OPTN (Option Therapeutics) Beneish M-Score


What is Option Therapeutics Beneish M-Score?

Option Therapeutics does not have enough data to calculate Beneish M-Score.

Option Therapeutics Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Option Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Option Therapeutics Beneish M-Score Chart

Option Therapeutics Annual Data
Trend Jun24 Jun25
Beneish M-Score
0.00 0.00

Option Therapeutics Quarterly Data
Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

OPTN vs : Beneish M-Score Comparison

For the Biotechnology subindustry, Option Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Option Therapeutics Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Option Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Option Therapeutics's Beneish M-Score falls into.


Option Therapeutics Business Description

Comparable Companies
Address 680 West Nye Lane, Suite 201, Carson, NV, USA, 89703
Option Therapeutics Inc is a clinical-stage company developing inventive drug therapies to treat debilitating and life-threatening liver disease through its investigational drug candidate BIV201 (continuous infusion terlipressin). BIV201 is administered as a patent-pending liquid formulation of terlipressin with patents issued, to date, in the U.S., China, Japan, Chile, and India.